Constant Connaught Medical Technology

Henovcom is a private Guangzhou-based biotechnology company founded in 2013 that develops innovative therapeutics and enabling technologies spanning small-molecule drugs, long-acting injectable formulations, and mRNA delivery components. Its disclosed pipeline includes autotaxin inhibitors for idiopathic pulmonary fibrosis and solid tumors, a neuraminidase inhibitor for influenza, a long-acting anti-HBV injectable, and long-acting Parkinson's disease candidates derived from rasagiline-related chemistry. The company describes a technology base covering discovery chemistry, pharmacology, non-GLP safety evaluation, formulation, API process development, and GMP-like process development and manufacturing. In addition to its therapeutic pipeline, Henovcom has promoted mRNA-enabling technologies including its LZCap cap analog and ionizable lipid work for vaccines and protein replacement applications. Overall, it appears to be an innovation-focused Chinese biopharma operating at the intersection of drug discovery, formulation science, and nucleic acid delivery.